US 2014/0154692 A1 · DIAGNOSTIC METHODS FOR DETECTING CLOSTRIDIUM DIFFICILE

Abstract

The invention provides a method of detecting Clostridium difficile in a sample, comprising detecting the presence in said sample of one or more genes that have been identified as being specific to Clostridium difficile. Also provided is a method of diagnosing a Clostridium difficile infection in a subject, a method of determining the efficacy of a therapeutic regime being used to treat a Clostridium difficile infection and a method of testing for the presence of Clostridium difficile in a sample. Further provided are primer pairs and a kit suitable for use in such methods.

Claims12

Dependent claims

A method of testing for the presence of Clostridium difficile in a sample, said method comprising analysing said sample for the presence of one or more genes selected from the group consisting, of CD3609, CD3617, CD3618, CD3635, CD3638, CD0638, CD1424, CD1487, CD1543a, CD1794, CD1906, CD2046, CD2098, CD2216, CD2264, CD2274, CD2309, CD3188, CD3288, CD3367 and CD2961 or a product of said genes.

A primer pair selected from the group consisting of

(a) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
67 or nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
67;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
68 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
68;
(b) an isolated oligonucleotide comprising the nucleotide sequence of SEQ NO:
13 or a nucleotide sequence capable of hybridising, under high stringency conditions to the sequence complementary to SEQ ID NO:
13;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO 14 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 14;
(c) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO 15 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
15;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
16 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
16;
(d) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
17 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
17;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
18 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
18;
(e) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:19 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:19;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:20 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:20;
(f) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:37 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
37;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:38 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:38;
(g) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
39 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
39;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
40 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
40;
(h) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
41 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
41;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
42 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 42;
(i) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
43 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
43;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO;
41 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
44;
(j) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
45 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
45;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
46 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
46;
(k) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
47 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
47;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
48 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
48;
(l) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
49 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
49;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:50 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
50;
(m) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
51 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
51;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
52 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 52;
(n) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
53 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 53;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
54 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 54;
(o) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
55 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
55;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
56 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
56;
(p) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
57 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
57;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
58 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
58;
(q) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
59 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
59;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
60 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
60;
(r) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
61 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
61;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
62 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 62;
(s) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
63 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
63;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
64 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
64;
(t) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
65 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
65;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
66 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
66;
and
(u) an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO:
11 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO:
11;
and
an isolated oligonucleotide comprising the nucleotide sequence of SEQ ID NO 12 or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 12.

127 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/128,180Filed 25 Jun 2012

Priority

GB 1110712.523 Jun 2011

Published

5 Jun 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification3 codes

C12Q 1/689
For detection or identification of organisms: for bacteria
C12Q 2600/106
Oligonucleotides characterized by their use: pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q
Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Diagnostic methods for detecting clostridium difficile

Life of this patent

Diagnostic methods for detecting clostridium difficile

Life of this patent

Abstract

Claims12